Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Grepafloxacin (compound)

Name: grepafloxacin
PubChem Compound ID: 115008
Molecular formula: C19H25ClFN3O3
Molecular weight: 397.871 g/mol
161967-81-3; Grepafloxacin hydrochloride; OPC 17116; 173689-78-6; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride; Grepafloxacin hydrochloride (+-)-; Raxar; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride, (+-)-; Grepafloxacin Hydrochloride [USAN]
Name: grepafloxacin
Name (isomeric): DB00365
Drug Type: small molecule
Brand: Raxar
Category: Anti-Bacterial Agents, Quinolones, Antibiotics, Anti-Infectives
CAS number: 119914-60-2
Indication: For treatment of adults with mild to moderate infections caused by susceptible strains of <i>Haemophilus influenzae</i>, <i>Streptococcus pneumoniae</i>, or <i>Moraxella catarrhalis</i>.
Pharmacology: Grepafloxacin has in vitro activity against a wide range of gram-positive and gram-negative aerobic microorganisms, as well as some atypical microorganisms.
Mechanism of Action: Grepafloxacin exerts its antibacterial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, essential enzymes for duplication, transcription, and repair of bacterial DNA.
Absorption: Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.
Protein binding: 50%
Biotransformation: Primarily hepatic via CYP1A2 and CYP3A4. The major metabolite is a glucuronide conjugate; minor metabolites include sulfate conjugates and oxidative metabolites. The oxidative metabolites are formed mainly by the cytochrome P450 enzyme CYP1A2, while the cytochrome P450 enzyme CYP3A4 plays a minor role. The nonconjugated metabolites have little antimicrobial activity compared with the parent drug, and the conjugated metabolites have no antimicrobial activity
Half Life: 15 ± 3 hours
Toxicity: Withdrawn from the US market in 1999 due to associations with QTc prolongation and adverse cardiovascular events.
Affected organisms: Enteric bacteria and other eubacteria
Food interaction:
Take without regard to meals.
Drink liberally but avoid coffee.
Drug interaction:
ErythromycinIncreased risk of cardiotoxicity and arrhythmias
TrimipramineIncreased risk of cardiotoxicity and arrhythmias
PromazineIncreased risk of cardiotoxicity and arrhythmias
DisopyramideIncreased risk of cardiotoxicity and arrhythmias
DyphyllineGrepafloxacin may increase the effect of dyphylline.
show more »